No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ETNB240517P17500
- 8.00
- 0.000.00%
15min DelayTrading Oct 10 11:28 ET
0.00High0.00Low
0.00Open8.00Pre Close0 Volume7 Open Interest17.50Strike Price0.00Turnover281.13%IV-1.86%PremiumMay 17, 2024Expiry Date8.38Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.9016Delta0.0448Gamma1.07Leverage Ratio-0.0363Theta-0.0029Rho-0.96Eff Leverage0.0024Vega
Intraday
- 5D
- 1D
News
89bio to Participate in the BofA Securities 2024 Health Care Conference
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH
PDF Version Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ETSAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ET
89bio Coverage Assumed by B of A Securities at Buy
89bio Coverage Assumed by B of A Securities at Buy
Express News | B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
Comments
$89bio(ETNB.US$ 💀hope the strong buy suggestions promoter goto jail for fraud😭
According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$ $Viking Therapeutics(VKTX.US$ $Akero Therapeutics(AKRO.US$ $89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$ $Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$ $Viking Therapeutics(VKTX.US$ $Akero Therapeutics(AKRO.US$ $89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$ $Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$
7
$89bio(ETNB.US$ 👀 news
1
Read more